DR. LAL Path Labs
- ISIN
- INE600L01024
- Instrument key
- NSE_EQ|INE600L01024
as of 21/11/2026, 1:32:30 pm
- Open
- ₹1,950.00
- Day high
- ₹2,028.20
- Day low
- ₹1,940.00
- Prev. close
- ₹1,963.20
- Volume
- 2.65 L
- VWAP
- ₹2,012.21
02/Price history
Price chart
1 month · 30-minute candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.
- Change · 1M
- +8.30%1,836.60 → 1,989.00
- Period high
- ₹2,079.009/11/2026
- Period low
- ₹1,797.8026/10/2026
- From high
- -4.33%+10.64% from low
- Avg volume
- 22.9K63.26 L total
- Candles
- 276143 up / 130 down
Candle data276 rows of open, high, low, close and volumeShowHide
| 20 Nov 2026 | 2,008.60 | 2,010.50 | 1,987.30 | 1,989.00 | -0.98% | 23.20 | 16.7K |
| 20 Nov 2026 | 2,008.10 | 2,012.90 | 2,006.50 | 2,008.90 | +0.04% | 6.40 | 21.9K |
| 20 Nov 2026 | 2,024.80 | 2,024.80 | 2,006.00 | 2,008.20 | -0.82% | 18.80 | 22.0K |
| 20 Nov 2026 | 2,021.00 | 2,026.00 | 2,020.00 | 2,024.50 | +0.17% | 6.00 | 19.8K |
| 20 Nov 2026 | 2,025.20 | 2,025.80 | 2,017.20 | 2,021.00 | -0.21% | 8.60 | 18.5K |
| 20 Nov 2026 | 2,024.70 | 2,027.70 | 2,023.40 | 2,024.10 | -0.03% | 4.30 | 13.8K |
| 20 Nov 2026 | 2,020.80 | 2,026.40 | 2,019.40 | 2,024.70 | +0.19% | 7.00 | 14.7K |
| 20 Nov 2026 | 2,018.90 | 2,026.90 | 2,014.40 | 2,019.50 | +0.03% | 12.50 | 20.7K |
| 20 Nov 2026 | 2,012.30 | 2,028.20 | 2,010.70 | 2,017.50 | +0.26% | 17.50 | 41.3K |
| 20 Nov 2026 | 2,004.60 | 2,014.00 | 2,004.10 | 2,013.50 | +0.44% | 9.90 | 22.7K |
Historical price and volume data · Showing 1–10 of 276
03/Valuation & returns
Key ratios vs sector
Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.
Price ÷ earnings per share
Worse than sector by 4%
Price ÷ book value per share
Worse than sector by 302%
Net income ÷ total assets
Better than sector by 305%
Net income ÷ shareholders' equity
Better than sector by 167%
EBIT ÷ capital employed
Better than sector by 125%
Liquid assets ÷ current liabilities
Worse than sector by 90%
Enterprise value ÷ EBITDA
Worse than sector by 41%
04/Business
About the company
Sector: Healthcare Services
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The Company is engaged primarily in the business of running laboratories for carrying out pathological investigations in various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests, including Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and vitamin D Test. It has approximately 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab in Kolkata, Bangalore and Mumbai), 6,607 patient service centers, and 12,365 pick-up points (PUPs). Its customers include individual patients, hospitals, and corporate customers.
- ₹33,680 Cr
- $3.74B
reported in crore
reported in billion
Market capitalisation is reported at the sector-constituent level, not the standalone company level.
05/Profit & loss
Consolidated income statement
Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.
- Revenue · Sep 2026
- ₹908 Cr+9.47% vs Jun 2026
- Net profit · Sep 2026
- ₹194 Cr+13.72% vs Jun 2026
- Operating margin
- 28.7%was 27.6%
- Revenue CAGR · 4p
- 9.9%profit 28.5% · op 28.0%
| Revenue | 908 | 830 | 727 | 684 |
|---|---|---|---|---|
| Revenue growthreported | 9.5% | 14.2% | 6.2% | — |
| Operating profit | 261 | 229 | 160 | 124 |
| Operating profit growthreported | 13.9% | 42.9% | 28.8% | — |
| Operating marginderived | 28.7% | 27.6% | 22.0% | 18.2% |
| Net profit | 194 | 171 | 132 | 91 |
| Net profit growthreported | 13.7% | 29.0% | 44.6% | — |
| Net marginderived | 21.3% | 20.6% | 18.2% | 13.4% |
| EPS — basic₹/share, annual | — | — | 30.24 | — |
Figures in ₹ crore. Margin rows are computed from the reported values.
Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
| Revenue | 2,763 | 2,461 | 2,227 | 2,017 |
|---|---|---|---|---|
| Other Income | 101 | 93 | 69 | 42 |
| Total Revenue | 2,864 | 2,555 | 2,296 | 2,059 |
| Total Expenses | 2,165 | 1,930 | 1,790 | 1,715 |
| Profit Before Tax | 669 | 625 | 505 | 344 |
| Tax | 159 | 133 | 143 | 103 |
| Profit After Tax | 510 | 492 | 362 | 241 |
| EPS - Basic | 30.24 | 29.24 | 43.05 | 28.82 |
| EPS - Diluted | 30.20 | 29.20 | 42.98 | 28.74 |
This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.
06/Balance sheet
Consolidated balance sheet
Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.
- Total assets · Mar 2026
- ₹3,146 Cr+15.80% YoY
- Total liabilities
- ₹605 Cr
- Net worth
- ₹2,541 Cr
- Liabilities ÷ assets
- 19.2%lower means a lighter balance sheet
| Total assets | 3,146 | 2,717 | 2,456 | 2,386 |
|---|---|---|---|---|
| Total liabilities | 605 | 510 | 571 | 686 |
| Net worthderived | 2,541 | 2,206 | 1,885 | 1,700 |
| Liabilities ÷ assetsderived | 19.2% | 18.8% | 23.2% | 28.8% |
| Asset growthderived | 15.8% | 10.6% | 3.0% | — |
Figures in ₹ crore. Stacked chart height equals total assets.
Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
| Non-Current Assets | 1,580 | 1,353 | 1,329 | 1,412 |
|---|---|---|---|---|
| Current Assets | 1,566 | 1,364 | 1,127 | 973 |
| Total Assets | 3,146 | 2,717 | 2,456 | 2,386 |
| Current Liabilities | 451 | 402 | 465 | 470 |
| Net Current Asset | 1,116 | 961 | 662 | 503 |
| Non-Current Liabilities | 154 | 108 | 105 | 216 |
| Equity Capital | 2,541 | 2,206 | 1,885 | 1,700 |
| Total Equity & Liabilities | 3,146 | 2,717 | 2,456 | 2,386 |
Figures in ₹ crore unless the line item is per-share.
07/Cash flow
Consolidated cash flow
Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.
- Operating · Mar 2026
- ₹636 Cr+11.73% YoY
- Investing
- -₹422 Cr
- Financing
- -₹264 Cr
- Free cash flow
- ₹214 Croperating + investing
| Operating activities | 636 | 569 | 535 | 456 |
|---|---|---|---|---|
| Operating changereported | 11.7% | 6.3% | 17.4% | — |
| Investing activities | -422 | -303 | -24 | -287 |
| Investing changereported | -39.1% | -1149.1% | 91.5% | — |
| Financing activities | -264 | -334 | -414 | -283 |
| Financing changereported | 21.1% | 19.3% | -46.1% | — |
| Net cash flowderived | -50 | -68 | 97 | -114 |
| Free cash flowoperating + investing | 214 | 266 | 511 | 169 |
Figures in ₹ crore.
Full annual line itemsProfit before tax through closing cash balanceShowHide
| Profit before tax | 510 | 492 | 362 | 241 |
|---|---|---|---|---|
| Income before WC changes | 784 | 732 | 632 | 527 |
| Change in Assets | -37 | -18 | -13 | 25 |
| Change in Liabilities | 64 | 19 | 49 | 10 |
| Change in WC | 27 | 1 | 36 | 35 |
| Cash flow from Operations | 636 | 569 | 535 | 456 |
| Cash flow from Investing | -422 | -303 | -24 | -287 |
| Cash flow from Financing | -264 | -334 | -414 | -283 |
| Total Cash Flow | -50 | -68 | 97 | -114 |
| Cash (Start of the year) | 293 | 361 | 264 | 378 |
| Cash (End of the year) | 243 | 293 | 361 | 264 |
Figures in ₹ crore unless the line item is per-share.
09/Events
Corporate actions
Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.
| DividendInterim | ₹5.00 | 50.0% | 11 Nov 2026 | 11 Nov 2026 | 04 Nov 2026 | |
| DividendInterim | ₹5.00 | 50.0% | 30 Jul 2026 | 30 Jul 2026 | 24 Jul 2026 | |
| DividendFinal | ₹4.00 | 40.0% | 25 Jun 2026 | 26 Jun 2026 | 30 Apr 2026 | |
| DividendInterim | ₹3.50 | 35.0% | 05 Feb 2026 | 05 Feb 2026 | 30 Jan 2026 | |
| Bonus | 1:1 | — | 19 Dec 2025 | 19 Dec 2025 | 31 Oct 2025 |
10/Comparison
Peers & competitors
Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.
| APOLLOHOSPApollo Hospitals Enter. L | Healthcare Services | ₹9,200.00 | +5.29% | 14.13 L | ₹1,32,139 Cr | $14.68B | |
| MAXHEALTHMAX Healthcare INS Ltd | Healthcare Services | ₹1,081.00 | +3.88% | 95.32 L | ₹1,05,080 Cr | $11.68B | |
| MANIPALHOSManipal Health Enterpri L | Healthcare | ₹702.20 | +0.83% | 11.62 L | ₹92,366 Cr | $10.26B | |
| ASTERDMAster DM Quality Care Ltd | Healthcare Services | ₹779.30 | +5.41% | 26.66 L | ₹67,960 Cr | $7.55B | |
| FORTISFortis Healthcare Ltd | Healthcare Services | ₹825.00 | +1.87% | 22.88 L | ₹62,284 Cr | $6.92B | |
| MEDANTAGlobal Health Limited | Healthcare Services | ₹1,480.20 | +0.13% | 2.65 L | ₹39,829 Cr | $4.43B | |
| NHNarayana Hrudayalaya Ltd. | Healthcare Services | ₹1,945.00 | +3.84% | 7.85 L | ₹39,757 Cr | $4.42B | |
| KIMSKrishna Inst Of MED SCI L | Healthcare Services | ₹795.60 | +3.62% | 10.44 L | ₹33,483 Cr | $3.72B | |
| SYNGENESyngene International Ltd | Diversified | ₹451.70 | +3.28% | 25.58 L | ₹18,240 Cr | $2.03B | |
| MOLBIOMolbio Diagnostics Ltd | Healthcare | ₹1,495.50 | -2.02% | 7.01 L | ₹17,228 Cr | $1.91B |
Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10
11/Coverage
Company news
Articles published in the last seven days, paginated by the provider.
No news in the last seven days
Company news is available for a rolling one-week window.